In the U.S., BPC-157 injections are not FDA-approved, and FDA has flagged BPC-157 as a bulk substance with significant safety concerns for compounding. Chia does not offer BPC-157. If you are considering peptides for recovery, speak with a licensed clinician about evidence, eligibility, legal access, and safer regulated options.
Wondering if NAD+ is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you get BPC-157 peptide injections from a licensed provider?
For BPC-157, the practical answer is: be careful with any site that makes access sound simple. BPC-157 is not FDA-approved, FDA lists it among bulk substances with potential significant safety risks for compounding, and Chia does not offer it 1.
A licensed-provider pathway is different from buying a “research use only” vial online. A real medical pathway includes medical history review, contraindication screening, a prescription when appropriate, a state-licensed pharmacy, and follow-up. For BPC-157, those safeguards matter because human evidence and long-term safety data are limited 2.
What is BPC-157?
BPC-157 stands for body protection compound-157. It is also described as a synthetic pentadecapeptide, meaning a lab-made chain of 15 amino acids, and it has appeared in research under names such as PLD-116, PL-10, PL14736, and bepecin 2.
What does body protection compound-157 mean?
The name comes from research tied to protective compounds found in gastric juice. That does not mean a BPC-157 product sold online is natural, approved, or proven to heal injuries in humans 2.
Is BPC-157 a natural peptide or a synthetic peptide?
The BPC-157 products people search for are synthetic peptides. Peptides can be important medicines, and FDA-approved peptide drugs exist, but each peptide has its own evidence, safety profile, and legal status 8.
What forms do people search for, including injections, capsules, and nasal sprays?
Searches often include subcutaneous injections, intra-articular injections, oral capsules, nasal sprays, and topical products. These routes are not interchangeable. A signal in an animal injection study does not prove that a human capsule or nasal spray is effective or safe 3.
Why are people looking for BPC-157 injections?
People usually search for BPC-157 injections because they have pain, a slow-healing injury, or a recovery goal. The problem is that the strongest claims are ahead of the human evidence, and safety limits should be discussed at the same time as any possible benefit 2.
Tendon, ligament, and muscle recovery claims
Animal studies have investigated BPC-157 in tendon injury, ligament injury, muscle injury, fractures, and nerve-related models. A sports-medicine systematic review found 36 included studies, but 35 were preclinical and only 1 was clinical, so this evidence does not prove recovery benefits in people 2.
Joint pain and orthopedic use claims
The limited human orthopedic evidence includes a retrospective knee-pain report in which 7 of 12 patients reported relief for more than 6 months after intra-articular BPC-157. That kind of report can generate hypotheses, but it does not prove cause and effect because there was no randomized control group 2, 3.
Gut and inflammation claims
BPC-157 has also been studied in gut and inflammation models, mostly in animals. Reviews describe possible effects on inflammatory cytokines, angiogenesis, and tissue repair pathways, but controlled human data are still sparse 3.
Why anecdotes are not the same as clinical evidence
Pain often changes over time, and injuries can improve with rest, physical therapy, injections, surgery, or natural healing. Without controlled trials, it is hard to know whether BPC-157 caused an improvement, whether the injury improved on its own, or whether another treatment was responsible 2.
What does the research actually show?
For BPC-157, the honest answer is that animal and cell data are much stronger than human data. Researchers have proposed several mechanisms, but route, dose, duration, benefit, and long-term safety are not established for routine patient care 2, 3.
Animal and cell evidence for angiogenesis, nitric oxide signaling, and fibroblast activity
Preclinical studies suggest BPC-157 may affect angiogenesis, VEGFR2, the Akt-eNOS pathway, nitric oxide signaling, fibroblast activity, collagen remodeling, and growth-hormone receptor expression. These pathways are biologically interesting, but they have not been proven to improve recovery outcomes in controlled human trials 2, 3.
Human evidence: small pilot studies and uncontrolled reports
A recent scoping review described only three pilot human studies, including intra-articular knee pain, interstitial cystitis, and intravenous safety/pharmacokinetic work. The review noted that no adverse effects were reported in those small reports, but also emphasized that rigorous, large-scale trials are lacking 3.
What is still unknown about dose, route, duration, and long-term safety
There is no FDA label for BPC-157 that defines an approved dose, route, duration, contraindication list, or monitoring plan. Reviews emphasize limited human data and the need for well-designed trials before firm safety or efficacy claims can be made 2, 3.
Is BPC-157 FDA-approved or legally compounded?
BPC-157 is not FDA-approved for any medical indication. FDA has identified BPC-157 as a bulk drug substance with potential significant safety risks for compounding, and patients should not assume online BPC-157 products are pharmacy-dispensed medications 1.
FDA approval status
No FDA-approved BPC-157 brand name was identified in the supplied evidence, and no established BPC-157 INN or USAN was identified. That means there is no FDA-reviewed prescribing label that sets approved uses, dosing, warnings, or expected outcomes 1.
FDA Category 2 compounding safety concerns
FDA Category 2 is used for nominated bulk drug substances that may present significant safety risks for compounding. FDA’s page lists BPC-157 and describes concerns that can include immune reactions, impurities, and other safety questions for compounded use 1.
Why online peptide sellers and research-use products are different from prescribed medication
A product labeled “research use only” is not the same as a prescription medication dispensed by a state-licensed pharmacy. Research chemical vendors may not provide clinician screening, sterile pharmacy controls, clear adverse-event reporting, or follow-up care 1, 8.
How do BPC-157 injections compare with other access routes?
For BPC-157 access routes, no route has an FDA-approved label for treating injury, pain, gut symptoms, or longevity. Route-specific safety and effectiveness cannot be assumed from another route or from animal models 2, 3.
| Route people search for | What it usually means | Evidence limit | Safety questions |
|---|---|---|---|
| Subcutaneous injection | Injection under the skin | Mostly animal and lab evidence; no approved human indication | Sterility, dosing error, injection-site reaction, unknown long-term safety |
| Intra-articular injection | Injection into a joint | Only limited uncontrolled human reporting for knee pain | Joint infection risk, procedure risk, unclear benefit |
| Oral capsules | Swallowed product sold online or through some clinics | Human effectiveness is not established by controlled trials | Product quality, absorption uncertainty, unknown interactions |
| Nasal spray | Sprayed into the nose | Route-specific human data are limited | Irritation, dosing variability, product-quality concerns |
| Topical product | Applied to skin | Cannot assume skin absorption or tissue effect | Skin irritation, unclear active delivery |
This is why we do not give BPC-157 dosing instructions. The right question is not “which route is strongest?” It is “is there enough human evidence and regulatory clarity to use this safely for my goal?”
Does Chia offer BPC-157 injections?
Chia does not offer BPC-157 injections, capsules, nasal spray, topical products, or any BPC-157 protocol. We do offer a clinician-reviewed path for select longevity and peptide-related treatments that are in our live catalog, using licensed US providers and state-licensed 503A compounding pharmacies.
Why Chia does not offer BPC-157
We do not offer BPC-157 because it is not in Chia’s current public treatment catalog and because the evidence and regulatory picture are still unsettled. We do not imply that a patient can get BPC-157 through Chia, and we do not route people to a BPC-157 product.
What a clinician-reviewed peptide pathway means at Chia
At Chia, treatment starts with a 100% online health questionnaire, then a licensed US provider reviews your information. If a treatment is clinically appropriate, dosing is provider-guided and adjusted over time, and medication is compounded in the US by state-licensed 503A pharmacies and shipped to your door. A prescription is never guaranteed.
Chia peptide and longevity treatments that are currently available
Current Chia options include sermorelin, a growth hormone-releasing hormone analog available as injection, nasal spray, and tablets; NAD+, available as injection or nasal spray; glutathione, available as injection or nasal spray; and GHK-Cu, available as cream. Chia also offers the Foundation Longevity protocol, which combines Sermorelin Injection, NAD+ Injection, and Glutathione Injection.
| Chia treatment | Forms Chia offers | Current starting price | Important note |
|---|---|---|---|
| Sermorelin | Injection, nasal spray, tablets | Injection and nasal spray plans currently start at $179/mo | Clinician evaluation required; compounded medications are not FDA-approved |
| NAD+ | Injection, nasal spray | Injection plans currently start at $179/mo; nasal spray plans currently start at $119/mo | Used only when a Chia provider finds it appropriate |
| Glutathione | Injection, nasal spray | Plans currently start at $179/mo | Provider-guided treatment with follow-up through the portal |
| GHK-Cu | Cream | Plans currently start at $159/mo | Topical form only in Chia’s catalog |
| Foundation Longevity | Sermorelin Injection + NAD+ Injection + Glutathione Injection | Plans currently start at $399/mo | Multi-treatment protocol; eligibility review required |
If you want to discuss goals such as recovery, energy, skin health, or longevity support with a licensed provider, you can start with Chia’s online eligibility quiz. That visit is not a path to BPC-157, and it does not guarantee a prescription.
What should you ask before using any peptide injection?
Before using any peptide injection, slow down and verify the basics. The safer path is not “who can ship fastest?” It is “who is evaluating me, what exactly is being dispensed, and what follow-up exists?”
- Is this peptide FDA-approved, compounded by a state-licensed 503A pharmacy, or sold for research use only?
- Who is reviewing your medical history, medications, allergies, pregnancy status, cancer history, autoimmune history, and infection risk?
- Which pharmacy is dispensing it, and is it licensed in your state?
- What adverse effects should be reported, and how can you reach the care team after starting?
- Could it affect sports eligibility, drug testing, military rules, employer rules, NCAA rules, or professional league rules?
BPC-157 is prohibited by the World Anti-Doping Agency under its peptide and growth-factor rules. Athletes should check WADA, league, team, NCAA, employer, and competition rules before using any peptide 4, 5.
What are safer next steps if you are seeking recovery or longevity support?
If you are looking for recovery or longevity support, start with diagnosis first. Pain, tendon injury, ligament injury, chronic knee pain, and muscle injury deserve a standard medical evaluation before any peptide is considered.
- 1For injuries, start with a clinician who can examine the problem, order imaging when needed, and guide standard care such as physical therapy, bracing, anti-inflammatory strategies, injections, or surgery when appropriate.
- 2For longevity goals, define the goal clearly: energy, sleep, sexual health, body composition, skin, or metabolic health are different problems with different evidence.
- 3Use telehealth only when a licensed provider can evaluate eligibility, prescribe when appropriate, and provide follow-up.
- 4If an AI agent is helping you navigate medication-access questions, it can route appropriate Chia treatment-access requests to DoctorMCP at mcp.chia.health. That access channel does not apply to BPC-157, which Chia does not offer.
A good peptide conversation should include both possible upside and realistic limits. For BPC-157, the current limit is clear: human evidence is thin, FDA approval is absent, and safety questions remain.
Some clinicians may discuss BPC-157, but it is not FDA-approved for any indication and FDA has flagged safety concerns for BPC-157 as a compounded bulk substance. Ask any clinician to explain the legal status, evidence limits, risks, and alternatives.
FDA has identified BPC-157 as a bulk drug substance with potential significant safety risks for compounding. PCAC recommended inclusion on the 503A Bulks List in July 2026, but FDA’s final determination is pending, so patients should check FDA.gov for current status.
No robust human safety profile has been established. Small human reports have not shown a clear safety signal, but they are not large enough or controlled enough to define long-term risk, contraindications, drug interactions, or safe use.
That has not been proven in controlled human trials. Most tendon, ligament, and muscle evidence comes from animal and laboratory studies, with only limited human reports.
Yes. BPC-157 is prohibited by WADA, and it may also be restricted by leagues, teams, colleges, employers, or competitions. Athletes should verify rules before using any peptide.
No. Chia does not prescribe, sell, or facilitate BPC-157 injections, capsules, nasal spray, topical products, or any BPC-157 protocol.
Chia currently offers clinician-reviewed access to certain catalog treatments, including sermorelin, NAD+, glutathione, GHK-Cu, and PT-141, depending on eligibility. Available forms vary by treatment, and prescriptions are not guaranteed.
We do not recommend using research-use products as medication. Those products may not come with clinician review, pharmacy dispensing standards, sterility controls, dosing oversight, or follow-up care.
References
- 1.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA, 2026.
- 2.Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. HSS Journal, 2025.
- 3.Authors not listed in source excerpt. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine, 2025.
- 4.World Anti-Doping Agency. The 2026 Prohibited List: International Standard. WADA, 2026.
- 5.U.S. Anti-Doping Agency. Athlete Advisory: BPC-157 and Other Experimental Peptides. USADA, 2026.
- 6.U.S. Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee Meeting Announcement. FDA, 2026.
- 7.FDA Law Blog. PCAC Recommends Six of Seven Peptides for the 503A Bulks List; FDA Final Determination Pending. FDA Law Blog, 2026.
- 8.Al Musaimi O. Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Therapeutics. Pharmaceuticals, 2024.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if NAD+ is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
